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In the search for therapeutic modifiers, frontotemporal dementia (FTD) has traditionally
been overshadowed by other conditions such as Alzheimer’s disease (AD). A clinically
and pathologically diverse condition, FTD has been galvanized by a number of recent
discoveries such as novel genetic variants in familial and sporadic forms of disease and the
identification of TAR DNA binding protein of 43 kDa (TDP-43) as the defining constituent
of inclusions in more than half of cases. In combination with an ever-expanding knowledge
of the function and dysfunction of tau—a protein which is pathologically aggregated in
the majority of the remaining cases—there exists a greater understanding of FTD than
ever before. These advances may indicate potential approaches for the development
of hypothetical therapeutics, but FTD remains highly complex and the roles of tau and
TDP-43 in neurodegeneration are still wholly unclear. Here the challenges facing potential
therapeutic strategies are discussed, which include sufficiently accurate disease diagnosis
and sophisticated technology to deliver effective therapies.
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INTRODUCTION
Frontotemporal dementia (FTD) is the third most common
dementia in modern society, rendering it a critical public
health issue (Onyike and Diehl-Schmid, 2013). However there
is currently a dearth of therapeutics in clinical trials that are
intended for FTD. Although tau has long been recognized as
the principle component of neurofibrillary tangles (NFTs) in
FTD (Joachim et al., 1987) and mutations in the microtubule
associated protein tau (MAPT) are responsible for a subset of
FTD cases (Hutton et al., 1998; Spillantini et al., 1998; D’Souza
et al., 1999), investment in tau therapies has traditionally lagged
somewhat due to the focus on proteotoxicity of other aggre-
gated proteins such as amyloid-beta (Aβ) in Alzheimer’s dis-
ease (AD; Schneider et al., 2014). Furthermore, the majority
of advances in genetics—so often a guiding hand for neurode-
generative research in the identification of therapeutic targets—
have occurred only relatively recently in FTD (Hutton et al.,
1998; Watts et al., 2004; Baker et al., 2006; Cruts et al., 2006;
Sreedharan et al., 2008; DeJesus-Hernandez et al., 2011; Renton
et al., 2011), and have uncovered genes such as progranulin
(GRN) and Tar DNA binding protein (TARDBP) with little
preexisting neurological literature. For example, mutation of
the gene TARDBP is pathogenic in amyotrophic lateral scle-
rosis (ALS; Sreedharan et al., 2008) and the encoded protein
TAR DNA binding protein of 43 kDa (TDP-43) has been iden-
tified as a major component of the ubiquitinated inclusions
that characterize approximately half of all FTD cases (Taniguchi
et al., 2004; Shi et al., 2005; Neumann et al., 2006); how-
ever, only 12 publications on this protein existed prior to this
discovery.
Findings such as these can drive promising therapeutic
research. Our understanding of the clinical symptoms, neu-
ropathological features and genetic contributions to FTD has
vastly expanded. At this point, we should be asking if we have
reached the critical mass of knowledge necessary to develop
effective therapeutics for clinical trials and, if not, we must assess
what the remaining hurdles are for therapeutic efforts to have the
highest probability of success. The ability to do so will depend not
only on developing bioactive compounds, but also on sufficiently
accurate diagnosis to determine those persons in early, if not
asymptomatic, stages of degenerative disease. While strides are
being made in many of these areas, there are still numerous chal-
lenges that must be met prior to effective therapeutic intervention
to treat this chronic, multifaceted condition. Fortunately, lessons
learned from the failures of clinical trials in neurodegenerative
diseases such as AD can inform clinical efforts for FTD.
CURRENT PHARMACEUTICAL INTERVENTION IN FTD
The current trialed therapy to date for FTD is based on man-
agement of symptoms and does not address cause, and the
rationale for their use is based on efficacy in treating other neu-
rodegenerative disorders or psychiatric conditions with similar
behavioral phenotypes. All of the clinical trials have been small,
and only a handful has been placebo-controlled, double blind
trials (Rabinovici and Miller, 2010). Generally, there is some
evidence to suggest that selective serotonin reuptake inhibitors or
serotonin norepinephrine reuptake inhibitors may be beneficial
for some patients, particularly those with behavioral disturbances
(Boxer and Boeve, 2007; Vossel and Miller, 2008). Antipsychotics
and drugs targeting the cholinergic system appear to be largely
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ineffective (Mendez et al., 2007). Furthermore, despite its off-
label use to treat FTD, the largest clinical study to date found
no benefit to patients of taking memantine (Boxer et al., 2013).
Consequently, there is no definitive treatment for FTD, and there
is a dire need for novel therapeutics that target the underlying
causes.
CLINICAL FTD AND PATHOLOGICAL FTLD
CLINICAL AND PATHOLOGICAL HETEROGENEITY OF FTD/FTLD
FTD is a clinical term for a cluster of syndromes resulting from
degeneration of the frontal and temporal lobes. Although histori-
cally regarded as a disorder with presenile onset (prior to 65 years
of age), perhaps 25% of pathologically confirmed cases present
clinically later than this (Baborie et al., 2011; Onyike and Diehl-
Schmid, 2013).
Several syndromes can present in FTD which are associated
with specific regional atrophy (Kril et al., 2005; Pereira et al.,
2009; Seelaar et al., 2011). Behavioral-variant frontotemporal
dementia (bvFTD) is characterized by changes in personality and
behavior, and patients are apathetic (loss of interest in responsibil-
ities, social withdrawal) and disinhibited (demonstrating socially
inappropriate behavior) (Neary et al., 1998; Rascovsky et al.,
2011). Semantic dementia (SD) and progressive nonfluent apha-
sia (PNFA) comprise the two syndromes that are characterized by
changes in language function. SD presents with impaired com-
prehension and anomia, in contrast to PNFA in which language
comprehension is spared, but speech is effortful and grammati-
cally erroneous (Gorno-Tempini et al., 2011). These three variants
often overlap, particularly at later stages of disease as atrophy
becomes more widespread (Mesulam et al., 2003; Marczinski
et al., 2004; Banks and Weintraub, 2008). The FTD umbrella also
includes corticobasal syndrome (CBS) and progressive supranu-
clear palsy syndrome (PSPS; Boeve et al., 2003; Josephs, 2008),
which while originally identified as atypical movement disorders
also frequently present with features of bvFTD or PNFA. Similarly,
individuals initially showing typical bvFTD/PNFA can develop
motor disturbances (Rabinovici and Miller, 2010). bvFTD is
frequently accompanied by an element of motor dysfunction as in
motor neuron disease (FTD-MND) (Geser et al., 2010). Thus, the
clinical picture of FTD is a spectrum of overlapping syndromes.
Underlying these clinical syndromes is a cluster of diseases
collectively termed frontotemporal lobar degeneration (FTLD).
In keeping with the historical approach to neurodegenera-
tive conditions, definitive diagnosis of underlying disease is
reserved for postmortem analysis based on pathological find-
ings (i.e., the nature of the protein aggregate in specific brain
regions). Pathologically, FTLD can now be broadly split into two
major categories; FTLD-TDP with neuronal and glial inclusions
immunoreactive for TDP-43, and FTLD-tau containing fibrillar,
hyperphosphorylated tau (Joachim et al., 1987; Cairns et al., 2007;
Neumann et al., 2007a). A small number of tau-negative, TDP-43-
negative cases comprise the remainder which are immunoreactive
to components of the ubiquitin proteasome system (FTLD-UPS),
the fused in sarcoma protein (FTLD-FUS), ubiquitin only (FTLD-
U) or lack inclusions completely (FTLD-ni/FTLD-other) and
which will not be discussed here (Holm et al., 2009; Urwin et al.,
2010; Josephs et al., 2011).
HETEROGENEITY OF FTLD-TAU
Further complexity of FTLD is evident in the nature of the
TDP-43 or tau inclusions themselves, which appear as a variety of
subtypes. In the case of tau lesions, FTLD-tau can be subdivided
further to CBD (Dickson et al., 2002), progressive supranuclear
palsy (PSP; Hauw et al., 1994), Pick’s disease (PiD; Dickson,
1998), argyrophilic grains disease (AGD; Braak and Braak, 1987,
1989), sporadic multisystem tauopathy (MST; Bigio et al., 2001)
and diffuse NFT dementia with calcifications (DNTC; Kosaka,
1994). PSP, CBD and PiD comprise by far the majority of cases
of FTLD-tau (Josephs et al., 2011). In addition to these spo-
radic diseases, FTD and Parkinsonism linked to chromosome
17 (FTDP-17t) is caused by mutations in MAPT—this genetic
form representing the cornerstone piece of evidence for the
involvement of tau in non-familial disease (Hutton et al., 1998;
Spillantini et al., 1998; D’Souza et al., 1999). Each of these
conditions is characterized by the appearance of hyperphospho-
rylated tau that self-aggregates into fibrillar paired helical fila-
ments (PHFs) and consequently neurofibrillary tangles (NFTs),
although the morphology of the inclusion differs amongst dis-
eases. Some of this heterogeneity is derived from alternative splic-
ing of exon 10 of MAPT, which encodes one of the four “repeat”
regions that act as microtubule binding domains (Goedert et al.,
1989; Kosik et al., 1989). The deposited tau in PiD is rounded in
nature and cytoplasmic, and is unique in that it primarily contains
only 3 of the repeats (exclusion of exon 10, “3R” tau) (Delacourte
et al., 1998; de Silva et al., 2006). Inclusions of PSP and CBD
are both primarily composed of tau containing exon 10 and thus
all four repeat regions (“4R” tau) (Sergeant et al., 1999). Using
numerous antibodies to phosphorylated epitopes of tau, it has
been proposed that the antigenicity of inclusions in PSP and CBD
are similar to one another yet distinct from other tauopathies such
as AD (Berry et al., 2004). Subtle differences between the two may
be discerned on the basis of the nature of the inclusion. Neuronal
inclusions in PSP are large and globose, and are accompanied
by astrocytic lesions termed “tufted astrocytes”; whereas, CBD is
characterized by more rounded “cortico-basal bodies” in neurons
and “astrocytic plaques” (Yamada et al., 1992, 1993; Dickson et al.,
1996; Josephs et al., 2011). It is worth reiterating here that there is
a distinction between the pathological terms such as FTLD, CBD
and PSP and the clinical terms FTD, CBS and PSPS as they are
often incorrectly used interchangeably and can lead to confusion
if, for example, CBD or PSP is the underlying pathological disease
in a clinical case of PNFA (Josephs et al., 2011 and see also
“Current Clinical, Imaging and Biochemical Diagnostics” section
below on correlation between clinical symptom and neuropatho-
logically diagnosed disease).
HETEROGENEITY OF FTLD-TDP
A major component of inclusions in cases of FTLD with ubiquiti-
nated aggregates, which represents approximately 50% of FTLD
cases, was identified in 2006 to be TDP-43, giving rise to the
name FTLD-TDP (Neumann et al., 2006). There are four sub-
types of FTLD-TDP, associated with distinct TDP-43 pathological
morphology and distribution—Type A is characterized by many
aggregated, juxtanuclear, neuronal cytoplasmic inclusions (NCI)
and short dystrophic neurites (DN) predominantly in layer 2 of
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the cortex, Type B by fewer NCI and DN that are dispersed more
widely throughout the cortex, Type C by long DN in cortical
layer 2 and Type D by the appearance of neuronal intranuclear
inclusions (Mackenzie et al., 2011). Type D is typically found in
rare, familial cases involving mutations in the valosin containing
protein (VCP) gene (Forman et al., 2006), thus the defining
hallmark of sporadic FTLD-TDP is cytoplasmic aggregation as
NCI or DN. This is accompanied by a loss of nuclear TDP-43
expression (Neumann et al., 2006). In FTLD-TDP, TDP-43 is
also hyperphosphorylated and truncated to produce ∼25 kDa C-
terminal fragments, which appear to be enriched in inclusions
relative to the N-terminus (Igaz et al., 2008). Therefore, as is the
case for FTLD-tau, TDP-43 neuropathology appears as a number
of distinct entities and pathological subtypes. The toxicity of TDP-
43 and tau in disease is not evident from neuropathology alone,
and critical evidence for the involvement of both in disease hinge
on compelling genetic data.
FTLD GENETICS AS A DRIVER OF TRANSLATIONAL
RESEARCH
Studies of the genetic component of FTLD have provided impor-
tant breakthroughs in our understanding of disease pathogenesis.
As noted above, familial mutations in the MAPT gene encoding
the tau protein explain a subset of FTLD cases and provide com-
pelling evidence for the involvement of tau in sporadic disease,
which share some of the same pathological hallmarks (Hutton
et al., 1998; Spillantini et al., 1998; D’Souza et al., 1999). Whilst
inherited mutations in the TARDBP gene encoding TDP-43 are
not found in heritable FTLD, familial cohorts do exist in ALS, a
second TDP-43 proteinopathy (Sreedharan et al., 2008), implicat-
ing TDP-43 in neuronal dysfunction or death. This is used, in a
manner analogous to that for tau and AD, as evidence that TDP-
43 dysfunction is a driver of FTLD also. Since ALS and FTD are
now considered at opposite ends of the same disease spectrum,
the connection seems justified on a biological level also. Adding
further weight to this argument are reports of TARDBP mutations
in sporadic FTLD (Borroni et al., 2009a, 2010; Synofzik et al.,
2014).
Interestingly, familial cohorts do exist for TDP-43 positive
FTLD, although the mutations in this case are in the VCP,
C9ORF72 and GRN genes (Watts et al., 2004; Baker et al., 2006;
Cruts et al., 2006; Neumann et al., 2007b; DeJesus-Hernandez
et al., 2011; Renton et al., 2011). From a therapeutic stand-
point, by far the most intriguing of these is the secreted glyco-
protein progranulin, primarily due to its neurotrophic activity
(Van Damme et al., 2008). It also has roles in the periphery
including in inflammation and wound healing (He et al., 2003;
Ahmed et al., 2007). GRN mutations can be insertions, deletions,
splice site, missense or nonsense and are scattered throughout
the gene (Baker et al., 2006; Cruts et al., 2006; Gass et al.,
2006; Mukherjee et al., 2006; Bronner et al., 2007; Bruni et al.,
2007; Rademakers and Rovelet-Lecrux, 2009). However, all are
predicted to result in reduction of functional progranulin (Baker
et al., 2006; Cruts et al., 2006; Rademakers and Rovelet-Lecrux,
2009). Loss of progranulin function in these familial cases causes
type A TDP-43 pathology (Mackenzie et al., 2006). Common
genetic variants in progranulin are also potential risk factors
for TDP-43 proteinopathies including sporadic FTLD (Brouwers
et al., 2008; Sleegers et al., 2008; Galimberti et al., 2010). Cur-
rently, mechanisms by which reduction in progranulin results in
neurodegeneration are unclear but principally center on a reduced
ability to recover from age-related stressors or damage (Ryan et al.,
2009; Laird et al., 2010; Kao et al., 2011; Jackman et al., 2013).
The discovery of mutations in GRN in 2006 left only one
linkage region on chromosome 9 unaccounted for in hereditary
cases of FTD. The delay in identifying the responsible C9ORF72
gene can be attributed to the nature of the mutation itself—an
intronic, hexanucleotide (GGGGCC) repeat expansion that was
undetectable by commonly used sequencing methods (DeJesus-
Hernandez et al., 2011; Renton et al., 2011). Both the antisense
and sense strands are transcribed from this genomic locus and
form nuclear RNA aggregates or “RNA foci” (DeJesus-Hernandez
et al., 2011; Gendron et al., 2013; Zu et al., 2013), which may cause
cell death via sequestration of functional RNA binding proteins
(Lee et al., 2013b). The expanded RNA also undergoes repeat-
associated non-ATG translation (RAN translation) to produce
aggregation prone polypeptides that form inclusions in human
FTD (Ash et al., 2013; Gendron et al., 2013; Mori et al., 2013;
Zu et al., 2013). Reducing levels of expanded transcripts is an
obvious therapeutic concept and one that has already proven
successful in vitro (Donnelly et al., 2013). Another group has
demonstrated antisense efficacy in motor neurons derived from
C9ORF72 carriers (Sareen et al., 2013). However, future stud-
ies that clarify the mechanistic link between RNA foci, RAN
proteins, and neurodegeneration will be essential in order to
determine if such approaches are likely to fully address the
neurotoxicity in C9ORF72 cases. It should be also noted that
the neuropathology unique to C9ORF72 is not present in FTD
lacking repeat expansion mutations. Although C9ORF72 muta-
tions constitute a fascinating additional mechanism by which
genetic aberration induces neuronal demise, therapeutic implica-
tions for FTD cannot currently be extrapolated to the population
at large.
In addition to these familial, causative mutations, there are a
number of genes that modulate the risk of FTD or phenotypic
outcome. Notably, homozygous mutations in TREM2 are asso-
ciated with atypical FTD presenting with epilepsy and parkin-
sonism (Giraldo et al., 2013; Guerreiro et al., 2013; Le Ber et al.,
2014). Rare heterozygous mutations in this gene may increase risk
of FTD (Lattante et al., 2013; Borroni et al., 2014; Cuyvers et al.,
2014). Several genes identified in genome wide association studies
may also modify risk (Ferrari et al., 2014).
TAU AND TAU-MEDIATED MECHANISMS OF TOXICITY
TAU BIOLOGY AND FUNCTION
The MAPT gene generates six isoforms of the microtubule bind-
ing protein tau via alternative splicing of exons 2, 3 and 10 (Kosik
et al., 1989). Exon 10 contains one of four microtubule binding
domains in tau, such that exon inclusion generates the 4R isoform
with higher affinity than 3R for microtubule binding, these two
forms being expressed at approximately 1:1 ratio in human adult
brain (Goedert et al., 1989; Goedert and Jakes, 1990; Butner and
Kirschner, 1991). The binding of tau stabilizes microtubules and
promotes assembly (Weingarten et al., 1975; Cleveland et al.,
Frontiers in Aging Neuroscience www.frontiersin.org August 2014 | Volume 6 | Article 204 | 3
D’Alton and Lewis Frontotemporal dementia: pathogenesis and therapy
1977). Under physiological conditions in healthy neurons, this
activity is further regulated by phosphorylation of tau at 47
confirmed sites (Martin et al., 2013) by a variety of major cellular
kinases including glycogen synthase kinase 3 beta (GSK-3β; Wag-
ner et al., 1996), microtubule affinity regulating kinase (MARK;
Drewes et al., 1997) cyclin dependent kinase 5 (CDK5; Baumann
et al., 1993), Protein Kinase A and C (PKA/PKC; Michel et al.,
1998) and by phosphatases such as protein phosphatase 2a (PP2A;
Sontag et al., 1996). Furthermore, our lab has recently demon-
strated that the Parkinson’s disease associated kinase LRRK2 can
phosphorylate tau (Bailey et al., 2013). Tau is regulated both in
normal and disease states by phosphorylation, with phosphory-
lated tau having reduced affinity for microtubules, preventing
their stabilization (Drechsel et al., 1992).
Although microtubule binding is the major function ascribed
to tau, it has a number of other roles, for example in influencing
cell signaling via kinases such as Fyn, Src (Sharma et al., 2007)
and phospholipase Cγ (Hwang et al., 1996). A nuclear form of
tau is also implicated in protection from stress (Sultan et al.,
2011), indicating that our current knowledge of tau function
is probably incomplete. Additionally, our knowledge of “what”
tau does is often interpreted without the context of “when”, an
important consideration when aiming to modify any activity but
particularly so in an age-related condition. For example, there are
numerous external inputs that may induce tau phosphorylation,
including oxidative stress (Melov et al., 2007), hypoxia (Fang
et al., 2010), hypothermia (Planel et al., 2007a), administration
of drugs (Whittington et al., 2011), insulin dysfunction (Planel
et al., 2007b) and viral infection (Patrick et al., 2011). Splice
exclusion of tau exon 10 also occurs in response to hypoxia
(Suh et al., 2010). These observations imply that tau is dynam-
ically regulated in response to external cues, which may be
important when evaluating scientific theories and therapeutic
avenues.
TAU AGGREGATION AND TOXICITY
The identification of which form(s) of tau are actually toxic
remains the largest question in the field, and is a key determinant
of future therapeutic avenues. Originally, tangles themselves or
smaller fibrillar antecedents were considered the species most
likely to be neurotoxic, and theories regarding direct toxicity
via physical blockade of cellular function such as trafficking,
disruption to organelle distribution and inhibition of proteasome
activity remain intuitive and often well-researched hypotheses
(Figure 1; Keck et al., 2003; Lin et al., 2003; Ren et al., 2007).
Despite this, several lines of evidence weigh against tangles
as a form of tau toxicity, or at least suggest that they are not
solely responsible. For example, neurons survive for perhaps
decades with neurofibrillary pathology (Morsch et al., 1999) and
silencing of the tau transgene in a mouse model of tauopathy
following formation of NFT pathology rescues cognitive pheno-
type, although tangle formation continues unabated (Santacruz
et al., 2005). Furthermore, several transgenic lines of mice and
tau transgenic flies expressing various tau isoforms display a
distinct dissociation between cell death and the appearance of
tangle pathology (Wittmann et al., 2001; Andorfer et al., 2005;
Spires et al., 2006). In fact, tangle-bearing neurons in mice
expressing mutant P301L tau appear to be functionally identical
to both wild type mice and to neighboring neurons that do
not contain NFTs (Kuchibhotla et al., 2014). Additionally, study
of human disease has demonstrated that despite greater tissue
loss in FTDP-17t, the aggregated tau burden in these cases is
approximately 10% of the level of that found in AD (Shiarli et al.,
2006). While these studies do not exclude the possibility that
tangles are ultimately toxic, they do suggest that tangles are not
the initial neurotoxic species. Rather, such findings have shifted
philosophy towards a less visible form of pre-fibrillar species,
with aggregated material representing compensatory adaptation
to sequester these smaller toxic forms, at least initially. Several
groups have reported the existence of what might be referred to
as tau oligomers (Berger et al., 2007; Maeda et al., 2007; Sahara
et al., 2007). Although the nature and importance of these species
are contentious, several studies have demonstrated an associa-
tion between their levels and neurotoxicity. For example, heat-
shock protein mediated stabilization of oligomers in the rTg4510
model of tauopathy is associated with enhanced neurotoxicity
but reduced fibril formation (Blair et al., 2013). Conversely,
immunotherapy in the JNPL3 transgenic mouse line of tauopathy
using an antibody to oligomeric forms of tau improves motor and
memory phenotypes without altering NFTs (Castillo-Carranza
et al., 2014).
POST-TRANSLATIONAL MODIFICATIONS, HYPERPHOSPHORYLATION
AND TAU LOSS-OF-FUNCTION
Tau modifications that occur prior to or concomitant with fib-
ril formation or oligomerization may potentiate toxicity. These
processing events include cleavage by caspases (Canu et al., 1998;
Rohn et al., 2002) and calpain (Park and Ferreira, 2005; Ferreira
and Bigio, 2011), O-linked glycosylation (Arnold et al., 1996; Liu
et al., 2004), ubiquitination (Morishima-Kawashima et al., 1993),
nitration (Horiguchi et al., 2003; Reyes et al., 2012), acetylation
(Min et al., 2010) and glycation (Ledesma et al., 1994; Yan et al.,
1994); however, the timing and significance of these modifications
in pathogenesis is frequently debated (reviewed in Gendron and
Petrucelli, 2009). The addition of such moieties and/or proteolytic
cleavage have been generally linked in some way to either facilita-
tion of tau into fibrillar species, the enhancement of subsequent
events such as phosphorylation or to modification of function
which might therefore facilitate the evolution of tau from func-
tional molecule to pathological toxin.
Of these, tau hyperphosphorylation is by far the most cited
candidate for a mediator of toxicity. Although phosphorylation
has been implicated in facilitation of fibril formation and aggre-
gation, which appears to differ between phosphorylation sites
(Alonso et al., 1996; Necula and Kuret, 2004, 2005; Wang et al.,
2007), pseudophosphorylated tau is also toxic in cell culture
without the need for fibril formation, demonstrating a pathogenic
effect of phospho-tau without fibrillization (Fath et al., 2002).
This has driven an alternative hypothesis that abnormal phos-
phorylation of tau results in inappropriate disengagement from
microtubules and consequent destabilization, which in turn
results in defects such as reduced axonal transport—in essence, a
tau loss of function. The absence of any robust neurodegenerative
phenotype in tau knockout mice may contradict this hypothesis,
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FIGURE 1 | Formation of pathological tau and potential therapeutic
interventions in FTLD. Tau bound to microtubules through repeat
regions (blue boxes, 4 repeat tau shown) exists in dynamic equilibrium
with physiological, phosphorylated tau (p-tau). P-tau formation is
accompanied by microtubule disengagement and depolymerization to
tubulin heterodimers. The point of equilibrium between tau and p-tau is
influenced by genetics and external factors such as oxidative stress and
hypothermia as well as stages of development. It is unclear if
hyperphosphorylated, disease-associated tau results from tipping of this
equilibrium to favor further p-tau formation, completely novel
phosphorylation pathways, or a mixture of the two. In the
hyperphosphorylated state, microtubule destabilzation beyond
physiological levels results in neuronal dysfunction. This loss of function
may be enhanced further by sequestration of functional tau by
hyperphosphorylated tau into oligomers, and subsequently fibrils and
aggregates. The repeat region of tau appears to form the core of these
insoluble species. A number of other covalent modifications
(ubiquination, nitration, glycation, phosphorylation, O-linked glycosylation)
and cleavage events (caspase and calpain) may also occur at ill-defined
junctures, and these may potentiate the dynamics of oligomerization or
aggregate formation. As there are a range of pathological tau lesions
which differ in appearance, these and other undefined pathways and
potentially factors such as genetics, environmental inputs and cell type
specific expression must differ in pathogenic tau formation. Pick bodies
are entirely three repeat tau. Pathogenic species or potentially toxic
mechanisms related to tau are highlighted in red. Blue dashed lines
denote potential therapeutic interventions, see main text for
more detail.
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although it seems plausible that constitutive loss of tau may be
compensated for by in utero-programmed upregulation of other
microtubule binding proteins such as MAP1a (Harada et al.,
1994). Interestingly, the absence of phenotype in this mouse is
also often cited as evidence that a potential therapy which reduces
total tau, and therefore any toxic species, would not yield adverse
consequences. The simultaneous assertion that loss of function
is a possible mechanism of disease and that reduction in total
tau should be considered for tau therapeutics is both highly
contradictory and highlights the current lack of clarity regarding
disease mechanism(s). In this specific instance, a conditional tau
knockout mouse may provide greater insight.
Nevertheless, loss of microtubule stability remains a plausible
neurodegenerative mechanism and phosphorylation of tau is a
proven destabilizer. Hyperphosphorylated tau extracted from AD,
another tauopathy, is a poor promoter of microtubule assembly
and sequesters normal functional tau and other microtubule
binding proteins in vitro (Alonso et al., 1996, 1997). Impor-
tantly, this effect is lost upon fibrillization or treatment with
phosphatases (Wang et al., 1996; Alonso Adel et al., 2006).
Activation of cdk5 in vivo using overexpression of p25 induces
tau phosphorylation with accompanying features characteristic of
loss of microtubule integrity (Ahlijanian et al., 2000; Bian et al.,
2002). Genetic evidence also supports the tau loss of function and
microtubule destabilization hypothesis. Mutations in MAPT that
are the cause of FTDP-17t typically are either intronic and alter
the splicing of exon 10 encoding one of the microtubule binding
domains or cause changes in coding sequences situated close to
the microtubule binding domain (Goedert, 2005). This suggests
that correct splicing of tau and consequently tau-mediated micro-
tubule stability is an important part of healthy aging. In many of
these familial cases, the aggregated tau is almost entirely of the 4R
form (Spillantini et al., 1997).
From the evidence above, it can be concluded that tau under-
goes a host of conformational and biochemical changes indi-
cating that in all likelihood there are a wide range of pathways
acting upon it at a number of different junctures (Figure 1).
During this evolution, tau may be toxic at one or several
points via a number of different mechanisms that may occur
simultaneously, and there is currently evidence supporting and
undermining each.
HYPOTHETICAL THERAPEUTIC STRATEGIES FOR FTLD-TAU
The critical issues surrounding toxicity pose significant con-
founds for the development of therapeutic approaches for FTLD-
tau. Hypothetical therapeutic strategies are at present based on a
highly complex toxicity that is not fully understood. At this time,
none of the aforementioned toxic mechanisms has emerged as the
dominant candidate in the push for therapy development. Con-
sequently, although there are a number of potential therapeutic
possibilities (Figure 1) there is no clear cut candidate above all
others for therapeutic intervention.
Under the gain of function aggregate toxicity model, determin-
ing toxic species will be highly influential in future direction. For
example, the removal of NFTs using a pharmacological “tangle
buster” of sorts might provide relief from the deleterious effects
of large aggregates. Nevertheless, if fibrillar or aggregate forms
of tau represent initial compensatory mechanisms to sequester
more upstream oligomeric forms, then it may be that removal
of this “toxic sink” would outweigh relief from tangle-associated
toxicity and would be consequently more harmful than beneficial.
Alternatively, small molecule inhibitors of oligomer formation
or fibrillization may prevent accumulation of all toxic species
at their origin. LMTX, a modified derivative of the aggregation
inhibitor methylthionine chloride (methylene blue), is entering
Phase III trials for bvFTD (clinical trial #NCT01626378, and see
Wischik et al., 2014). Other therapeutic avenues targeting toxic
species may be even more specific; immunotherapy is a poten-
tial method for the removal of pathological tau, and in several
instances has been demonstrated to suppress tau pathology and
improve phenotype in transgenic models of tauopathy (Asuni
et al., 2007; Sigurdsson, 2008; Yanamandra et al., 2013; Castillo-
Carranza et al., 2014). This strategy relies on identifying precisely
the species, or epitope of the species, responsible for toxicity and
successful application in human disease will rely on the resolution
of this issue. If multiple toxic species exist, which is quite possible
given the wide range of modifications that tau undergoes, then
multiple epitopes may need to be targeted.
The primary therapeutic alternative is based on the loss of
function model, making inhibition of phosphorylation and stabi-
lization of microtubules potential therapeutic options. Numerous
studies have demonstrated reduced hyperphosphorylation and
aggregation of tau with alleviation of motor phenotype or axonal
degeneration in murine models of tauopathy by inhibition of
tau kinases such as GSK3β, PKA and PKC (Nakashima et al.,
2005; Noble et al., 2005; Le Corre et al., 2006). Temsirolimus,
one of the newest potential therapies for tauopathy, appears to
work on two levels, through reducing tau hyperphosphorylation
and increasing autophagic clearance (Jiang et al., 2014). Although
there is concern regarding chronic inhibition of major regulatory
kinases with an approach such as this (McKnight et al., 2012),
initial studies suggest that GSK3 inhibitors such as lithium and
tideglusib are well tolerated in the short term (6–12 weeks) and
perhaps up to a year in patients with AD (MacDonald et al., 2008;
Hampel et al., 2009; Forlenza et al., 2011; del Ser et al., 2013).
Notably, lithium is already FDA-approved and could therefore
avoid many regulatory steps that typically retard drug availability.
Although these studies have demonstrated a lack of efficacy in
AD, duration of treatment has typically been short or using low
participant numbers. Microtubule stabilizing agents are currently
being actively pursued, and some appear to be brain penetrant
and improve microtubule density, axonal stability and cognitive
performance in mouse models of tauopathy (Brunden et al.,
2010a,b). However, the microtubule binding agent davunetide
(NCT01110720), which promotes assembly and affords neuro-
protection in a number of animal models, has recently failed
in Phase III trials for PSP (Shiryaev et al., 2009; Boxer et al.,
2014).
These strategies represent early therapeutic endeavors in
FTLD-tau. It is common in the literature to conclude research
articles by advancing new forms of tau pathology or the path-
ways affecting or affected by tau as potential therapeutic targets.
However, it is important to note the lack of evidence for a single,
dominant toxic mechanism. The complexity of FTLD-tau may be
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similar to that recently posed for AD, in which a heterogeneous
Aβ “soup” confers toxicity, rather than a single pathogenic species
(Benilova et al., 2012). In future, it will be important to refine
theories and identify mechanisms that contribute most signifi-
cantly to neuronal demise and that consequently have a higher
chance of success in clinical trials.
TDP-43 AND TDP-43 MEDIATED MECHANISMS OF TOXICITY
TDP-43 BIOLOGY AND FUNCTION
Previously a relatively little-studied protein, the stature of TDP-
43 has grown considerably due to description of mutations in
the TARDBP gene in sporadic and familial cases of ALS and the
discovery that TDP-43 is a major constituent of ubiquitin-positive
inclusions in FTD and ALS (Neumann et al., 2006; Sreedharan
et al., 2008). Subsequent demonstration that TDP-43 positive
aggregates are found in numerous other neurodegenerative dis-
orders including Parkinson’s disease and AD have consequently
raised the possibility that TDP-43 may be an intriguing thera-
peutic target outside of FTLD-TDP (Amador-Ortiz et al., 2007;
Nakashima-Yasuda et al., 2007). TDP-43 is also one of a number
of disease-related proteins with a known role in RNA metabolism
(Polymenidou et al., 2011), a field that over the last decade has
grown considerably in impact due to an increasing appreciation
for its complexity and influence in multiple biological systems.
The TARDBP gene encoding TDP-43 gives rise to a 414
amino acid nucleic acid binding protein containing a number
of functional domains including two RNA Recognition Motifs
(RRM), a glycine rich C-terminus required for binding to a host
of cofactors such as members of the hnRNP family and nuclear
localization and export sequences that contribute towards its
ability to shuttle continuously between nucleus and cytoplasm
(Buratti and Baralle, 2001; Ayala et al., 2008b; Winton et al., 2008;
Ling et al., 2010). A highly mobile protein, it is redistributed from
a predominantly nuclear localization to the cytoplasm in response
to diverse stress stimuli (Ayala et al., 2011) such as oxidative
stress (Liu-Yesucevitz et al., 2010), proteasome inhibition (van
Eersel et al., 2011), endoplasmic reticulum stress (Leggett et al.,
2012) and physical injury (Moisse et al., 2009) and relocalizes
at synapses upon depolarization (Wang et al., 2008). Studies in
humans and mice have demonstrated that TDP-43 binds a host
of RNA substrates, equal to approximately 30% of transcripts
in the mouse genome (Polymenidou et al., 2011). In addition
to mRNA, substrates also include non-coding elements such as
long noncoding, small nucleolar, small nuclear, ribosomal, micro
and telomeric RNA, and in some cases binding was increased in
cases of FTLD-TDP (Tollervey et al., 2011). In both mouse and
human studies, reduction in TDP-43 resulted in alterations in
splicing of bound transcripts (Polymenidou et al., 2011; Tollervey
et al., 2011). Binding of TDP-43 to pre-mRNA with large introns
results in stabilization in mice, and many of these transcripts
are involved in synaptic activity (Polymenidou et al., 2011).
Given that TDP-43 associates with a range of other proteins that
influence microRNA processing, splicing, polyadenylation and
RNA editing (Ling et al., 2010), it is likely that it is involved
in a plethora of cellular functions by sheer virtue of regulating
expression of transcripts in a number of ways that feed in to
numerous biological pathways. This is supported by functional
studies demonstrating that TDP-43 influences processes as diverse
as neurite outgrowth (Iguchi et al., 2009), cell cycle dynam-
ics (Ayala et al., 2008a), mitochondrial function (Duan et al.,
2010), metabolism (Chiang et al., 2010) and autophagy (Bose
et al., 2011). Evidently, TDP-43 is a critical regulator of cellular
dynamics.
TDP-43 AGGREGATION AND TOXICITY
Given the relatively recent discovery of TDP-43, understand-
ing the nature of its contribution to neurodegeneration is still
in its infancy. Current hypotheses regarding TDP-43 pathogen-
esis stem from observation of post-mortem changes in pro-
tein immunohistochemistry and biochemistry, and thus center
on direct toxicity from cytoplasmic aggregates or C-terminal
fragments and loss of nuclear function. These are not neces-
sarily mutually exclusive and may act in concert. C-terminal
fragments of TDP-43 are aggregate-prone, undergo phospho-
rylation and ubiquitination and are cytotoxic in cell culture
(Igaz et al., 2009; Nonaka et al., 2009; Zhang et al., 2009).
Disease linked mutations found in ALS appear to increase the
production of C-terminal fragments, and their aggregation and
toxicity (Johnson et al., 2009; Nonaka et al., 2009; Barmada
et al., 2010). The nature of these fragments and their gen-
eration is contentious. TDP-43 can be cleaved by caspases to
generate ∼25 kDa and ∼35 kDa fragments, and immunopos-
itive inclusions for the caspase-cleaved conformer are found
in human cases of FTLD-TDP (Zhang et al., 2007; Dormann
et al., 2009), with one group suggesting that this cleavage may
be neuroprotective in some way, perhaps by limiting TDP-43
activity (Suzuki et al., 2011). However, sequencing of fragments
from FTLD-TDP cases has yet to identify a single consensus
N-terminus amino acid for these fragments (Nonaka et al.,
2009). This may be consistent with observations using phospho-
specific antibodies which demonstrate multiple fragments from
17–25 kDa, the intensity of which also may be distinct for
each TDP-43 subtype (Hasegawa et al., 2008). Such hetero-
geneity may ultimately be important given that cleavage site
determines extent of phosphorylation, solubility and aggrega-
tion in vitro (Furukawa et al., 2011a). Although cleavage and
aggregation of TDP-43 is a pathological event, such properties
may also be involved in normal cellular function. Two groups
have reported on the prion-like nature of the C-terminus, which
self-interacts to form insoluble yet functional nuclear aggregates
that are repeatedly formed and destroyed (Wang et al., 2012;
Nonaka et al., 2013). Inhibiting or stabilizing this interaction
is proposed to cause degradation to 25 kDa or oligomerization
respectively. This segment of protein also confers structural beta-
sheet conformations that appear to promote the formation of
amyloid fibrils, and this propensity is enhanced by the A315T
mutation found in familial ALS (Guo et al., 2011). Thus, func-
tion and pathogenicity may be two sides of the same coin,
and the prion nature of TDP-43 opens up the intriguing pos-
sibility of prion-like spreading of disease (Nonaka et al., 2013).
One group has further suggested that prion-like aggregation
of TDP-43 or C-terminal fragments may be modulated by a
dynamic interaction with heat shock proteins (Udan-Johns et al.,
2014).
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TDP-43 LOSS OF FUNCTION AND TOXICITY
At least three studies using aggregate-prone C-terminal fragments
or in vitro-generated fibrillar TDP-43 have demonstrated that
aggregates are capable of sequestering the full length protein, and
therefore depleting endogenous nuclear function (Nonaka et al.,
2009; Che et al., 2011; Furukawa et al., 2011b), although this is
not true for all studies (Zhang et al., 2009). Consequently, the
reason for nuclear depletion is not fully understood, but is likely
to be deleterious given that numerous studies in vitro and in vivo
suggest TDP-43 levels necessitate tight regulation. Overexpression
and knockdown in vitro can confer toxicity (Ayala et al., 2008a;
Suzuki et al., 2011) and most persuasively knockout in vivo results
in lethality. This occurs both in conditional knockout animals
in which deletion is postponed until adulthood and in utero in
constitutive Tardbp−/− mice (Chiang et al., 2010; Kraemer et al.,
2010; Sephton et al., 2010; Wu et al., 2010). Loss of TDP-43
specifically in motor neurons results in cell death and an ALS-
like phenotype in mice (Wu et al., 2012) and reduced TDP-43
expression in Drosophila and zebrafish results in motor deficits
(Feiguin et al., 2009; Kabashi et al., 2010). These data suggest
that TDP-43 may be a critical regulator of cellular function
and pathological loss of function may have severe consequences
for cellular integrity. Furthermore, loss of TDP-43 activity may
result in altered response to cellular stress, as reduced TDP-43
levels results in reduction in the number and size of stress gran-
ules (SGs), transient cytoplasmic bodies involved in RNA triage
that form in response to oxidative stressors (McDonald et al.,
2011). Reduction of TDP-43 in primary neuronal cell culture also
increases sensitivity to toxic proteasome inhibition (van Eersel
et al., 2011). Both of these cellular insults may be involved in the
initial formation of TDP-43 pathology. SGs, which contain TDP-
43 itself, may form the initial “seeds” for subsequently greater
aggregation whilst proteasomal inhibition also induces nuclear
clearance and cytoplasmic aggregation of TDP-43 in vivo and in
vitro (Liu-Yesucevitz et al., 2010; Meyerowitz et al., 2011; Parker
et al., 2012; Tashiro et al., 2012).
Thus, as for tau, there are potentially a number of different
mechanisms by which TDP-43 dysfunction contributes to neu-
ronal demise, and which may not be mutually exclusive. Recently
the tau field has reached a point of equilibrium with regards to
the loss of function vs. gain of toxicity debate. It will be intriguing
to see in the near future if there is a definitive answer for TDP-43
proteinopathies.
THERAPEUTIC STRATEGIES FOR FTLD-TDP
Understanding of TDP-43 proteinopathy or even TDP-43 endoge-
nous function is currently limited and thus so are therapeu-
tic expectations. However, plausible logical suggestions would
be restoration of nuclear function and reduction in forma-
tion of or increased clearance of aggregates. As loss of TDP-
43 has significant implications for cellular integrity, aiming to
reduce expression and therefore aggregate formation, as pro-
posed for tau, is a conceptual non-starter. One may hypoth-
esize that preventing cytoplasmic accumulation and retaining
nuclear function may prove beneficial. In this case, simply
defining the mechanism by which loss of nuclear function
occurs is critical. If it is underpinned by cytoplasmic aggregate
sequestration, then targeting aggregated material would logi-
cally provide relief from both nuclear loss and any direct cyto-
toxicity. At least in vitro dimebon and methylene blue, two
compounds that were successful in Phase II clinical trials for
AD, are capable of reducing TDP-43 aggregation (Yamashita
et al., 2009). Currently, our knowledge of TDP-43 biology is
probably too limited to make TDP-targeted therapies a realistic
short term goal. Increased knowledge of basic function and the
development of more sophisticated study tools such as animal
models recapitulating TDP-43 pathology and patient specific
induced pluripotent stem cells (iPSCs) should provide a greater
understanding of pathways amenable to therapy (Bilican et al.,
2012; Egawa et al., 2012). Indeed, iPSCs have already been
used to screen drug candidates, identifying anacardic acid as a
potential modifier of insoluble TDP-43 species (Egawa et al.,
2012).
PROGRANULIN AS AN UNBIASED THERAPEUTIC
CANDIDATE
For both tau and TDP-43 directed therapies, there is a broader
question raised by the presence of multiple disease subtypes
(for example, CBD, PSP and PiD in FTLD-tau and type A-D
for FTLD-TDP). As the pathology for each disease differs, the
mechanisms leading to their formation may also be dissimilar.
Would a different therapeutic strategy be required for each, or
is there a keystone mechanism underpinning them all? This
question is analogous to that posed in the cancer field where
optimal breast cancer treatment paradigms depend on the type
of cancer present (Kelly and Buzdar, 2013). A therapy that could
be used more globally and that is not dependent on the type of
pathology might therefore have greater application. The discovery
of loss-of-function mutations in progranulin as a cause of TDP-
43 proteinopathy may provide such a target. When compared
with the challenge of identifying toxicity due to tau and TDP-43,
raising levels of the potentially neuroprotective progranulin is
a conceptually simple solution. Recent identification of TNF
(Tang et al., 2011) [although this interaction is disputed (Chen
et al., 2013)] and sortilin (Zheng et al., 2011) receptors that
bind progranulin offer potentially modifiable and druggable
targets. Indeed, small molecule inhibition of sortilin-mediated
endocytosis restores extracellular progranulin levels in iPSCs
derived from progranulin mutation carriers to wild type levels
(Lee et al., 2013a). Additionally, chemicals that upregulate pro-
granulin levels through enhanced transcription (suberoylanilide
hydroxamic acid) or the stabilization of intra- and consequently
extracellular progranulin by the alkalization of intracellular
compartments have been identified (chloroquine, bepridil, and
amiodarone), some of which are already FDA-approved (Capell
et al., 2011; Cenik et al., 2011). Finally, protective genetic variants
of the transmembrane protein TMEM106b were identified in
a genome wide association study of GRN mutation carriers.
These variants delay age of onset or reduce penetrance in GRN
mutation carriers and correlate with plasma progranulin levels,
implicating TMEM106b or interacting pathways as therapeutic
targets (Van Deerlin et al., 2010; Cruchaga et al., 2011; Finch
et al., 2011). The applicability of these or other future progranulin
therapies to neurodegenerative diseases outside of FTLD-TDP
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could be tested in vivo in animal models, with transgenic models
of tauopathy/FTLD-tau an obvious candidate.
A number of challenges present themselves. Primarily, little is
known regarding how progranulin is processed in the brain, with
the majority of knowledge coming from studies in the periphery.
In this environment, the progranulin precursor—composed of
seven and a half repeats of a common 12-cysteine module called
granulin—can be processed proteolytically by elastase and pro-
teinase 3 to produce the individual granulins (Kessenbrock et al.,
2008), which may have distinct effects on biological processes. At
present, it is unknown whether the same mechanisms occur in
the brain or whether loss of full-length progranulin or individual
granulin(s) is the cause of FTLD in familial forms. At least
two studies have suggested that the neurotrophic properties of
progranulin may be due to module granulin activity rather than
the full-length form (Gass et al., 2012; De Muynck et al., 2013).
If distinct biological effects exist for the full-length progranulin
precursor and each individual granulin, the results of elevating the
former in FTD patients may be a complex and multifaceted mix of
therapeutic and unintended side effects. It is consequently imper-
ative to either deconstruct the desirable mechanisms underlying
progranulin function or to demonstrate in vivo the safety, toler-
ability and physiological benefits of increased progranulin levels.
Encouragingly, mice overexpressing progranulin are significantly
rescued from the behavioral deficits induced by middle cerebral
artery occlusion stroke paradigms coincident with a shift to a
more anti-inflammatory profile in transgenic animals (Tao et al.,
2012; Egashira et al., 2013). This shift in inflammatory profile is
consistent with a role for progranulin in modulating neuroinflam-
matory responses (Cenik et al., 2012; Martens et al., 2012; Tanaka
et al., 2013). Progranulin knockout mice—a model of inherited
FTLD due to GRN mutation—provide a useful tool for studying
progranulin deficiency but lack overt TDP-43 aggregation and
nuclear clearance as observed in humans (Ahmed et al., 2010).
Pathology is restricted to hyperphosphorylated, insoluble TDP-
43 that remains largely nuclear (Wils et al., 2012). Such tools
may be necessary to fine tune elevation of progranulin levels,
given its potential role in tumorigenesis (Tangkeangsirisin and
Serrero, 2004; Matsumura et al., 2006; Göbel et al., 2013). In
sum, progranulin therapy is an attractive target for FTLD-TDP,
particularly so for families with heritable progranulin mutations,
but gaps remain in our understanding of disease that may need to
be resolved.
DIAGNOSTIC PROGRESS AND THE HURDLE OF
HETEROGENEITY
CURRENT CLINICAL, IMAGING AND BIOCHEMICAL DIAGNOSTICS
Of equal importance in therapeutic consideration is the ability
to diagnose individuals with specific disease. In this regard, neu-
ropathology remains the dominant driver of disease mechanism
theory and consequently therapeutic hypotheses, but determina-
tion of underlying FTLD-tau or FTLD-TDP early in the disease
process will be essential in any therapeutic endeavor. As alluded
to above, hypothetical therapies may also need to be designed
to individual subtypes of TDP and tau pathology, if no singular
process can be commonly delineated or effectively targeted. There
are a number of diagnostic approaches under consideration that
can be categorized as clinical, biological and those using imaging
technologies.
Clinical-pathological studies of FTD have advanced rapidly,
resulting in several changes in neuropathologic diagnostic and
nosologic criteria for FTLD to reflect these findings (Cairns
et al., 2007). There are probabilistic correlations between the
syndromes and diseases underlying them, which invites some
optimism in disease and subtype diagnosis in symptomatic indi-
viduals (Figure 2; Josephs et al., 2011). SD and FTD-MND are
almost exclusively FTLD-TDP whereas PSPS and CBS are almost
always characterized by tau pathology. PNFA and bvFTD are more
neuropathologically heterogeneous, which is unfortunate given
the high prevalence of bvFTD (in the largest clinicopathological
study to date, bvFTD represented around 45% of FTD). Fur-
thermore, in some cases there are correlations—albeit weaker
ones—between specific subtypes of tau or TDP-43 pathology
and clinical phenotype. For example, FTD-MND is not only
purely FTLD-TDP but is approximately 70% type B and TDP-
43 positive SD almost 85% type C (Josephs et al., 2011). Again,
bvFTD is a much more complex syndrome in terms of either
TDP-43 or tau subtype. However, one intriguing suggestion is
that FTLD-TDP and FTLD-tau may affect distinct, distant brain
networks and that detailed neuropsychological analysis may be
used to differentiate the network—regardless of the syndrome—
and hence pathology (Grossman et al., 2008; Listerud et al., 2009;
Seeley et al., 2009).
While such correlations are interesting on a population level,
there is clear heterogeneity in disease/syndrome pairing and
often overlap between syndromes, meaning there is currently
FIGURE 2 | Relationship between clinical FTD phenotype and
underlying FTLD disease neuropathology. For each clinical subtype on
the left, the bar is divided to show the approximate proportion of cases
which are underpinned by the indicated disease neuropathology. Profound
neuropathological heterogeneity exists for many clinical subtypes,
particularly bvFTD and PNFA. This figure is based on data from Josephs
et al. (2011).
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minimal utility in diagnosing pathology in the clinic for individ-
ual patients based solely on phenotype. Furthermore, potentially
the greatest issue for FTLD therapies—and neurodegenerative
disease in general—is that of timing of intervention. Clinical
trials in AD have generally reached the conclusion that the
current pharmacological therapies in trial may require earlier
administration if a clinical benefit is to be achieved. This may
require studies in pre-symptomatic patients, as the appearance
of pathology predates the manifestation of clinical symptoms by
some time, potentially as much as 15–20 years (Golde et al., 2011;
Bateman et al., 2012). Trials targeting earlier in AD now depend
upon the use of diagnostic screening to identify patients at risk
on the basis of preclinical disease biomarkers (Vellas et al., 2013).
Although the length of presymptomatic phase may differ, this is
distinctly probable in other chronic neurodegenerative diseases
such as FTLD (Jacova et al., 2013), thus the early identification of
people at risk of disease becomes crucial and will be underpinned
by either biochemical and/or imaging techniques.
Antemortem neuroimaging analysis using the Aβ plaque bind-
ing radioligands florbetapir and Pittsburgh compound B have
provided tremendous insight into pre-symptomatic disease pro-
gression in AD (Klunk et al., 2004; Bateman et al., 2012; Clark
et al., 2012). Although the field currently lacks a substrate specific
ligand for TDP-43, the recent development of a class of tau lig-
ands will surely expedite studies in prodromal tauopathy patients
(Maruyama et al., 2013). In the meantime, other imaging markers
such as atrophy of specific brain regions are proving on the group
level to correlate well with syndrome (Hu et al., 2011) and have
been used, for example, to demonstrate that there is phenotypic
heterogeneity linked to distinct atrophic patterns even within a
subgroup such as bvFTD (Whitwell et al., 2009b). Specifically
relating to disease prediction, results are currently inconclusive as
to whether atrophy can predict FTLD-tau or FTLD-TDP patho-
type (Grossman et al., 2007; Kim et al., 2007; Pereira et al., 2009;
Whitwell et al., 2009a), although it appears that TDP-43 subtypes
may be associated with distinct regional atrophy once FTLD-
TDP is neuropathologically confirmed (Whitwell et al., 2010).
These and other sophisticated techniques such as arterial spin
labeling (Hu et al., 2010b) and 18F fluorodeoxyglucose positron
emission tomography (Womack et al., 2011) may be useful in
the future for diagnosing underlying disease or for following
disease progression in therapeutic trials. However, as a diagnostic
tool in screening a presymptomatic population, they are highly
impractical due to expense and time consumption.
Ideally, the identification of biochemical biomarkers for the
discrimination of FTLD-tau or FTLD-TDP would provide a more
cost effective and less time consuming alternative to imaging and
work has begun in probable cohorts based on syndromic pre-
sentation and pathologically confirmed cases of FTLD. Although
TDP-43 appears to be raised in either plasma or CSF of clini-
cally defined FTD or FTD-MND populations, there is significant
overlap with control or AD subjects and it remains unclear
if such an approach will prove clinically useful (Foulds et al.,
2008; Steinacker et al., 2008). Similarly, results to date suggest
that total tau or tau phosphorylated at threonine 181 may not
be good candidates for discriminating FTLD-tau from control
(Vanmechelen et al., 2000; Bian et al., 2008; Kapaki et al., 2008).
Using unbiased proteomic approaches, it appears that FTLD-
TDP and FTLD-tau might be distinguished from one another
on the basis of several CSF analytes, although the specificity and
reliability of these remain to be determined in larger studies
(Hu et al., 2010a). It is also unknown whether the heterogeneity
of TDP-43 pathology (subtypes A-C) and FTLD-tau (PiD, CBS,
PSP) can be disaggregated at the biochemical level. For example,
it appears PSP may have a unique truncated tau profile in CSF
that separates it from other tau diseases (Borroni et al., 2009b)
although this has not been replicated in additional, independent
studies (Kuiperij and Verbeek, 2012).
TOWARDS MULTIDIMENSIONAL, PRESYMPTOMATIC DIAGNOSTICS
While these studies represent early forays into biomarker evalua-
tion, more powerful proteomic screening of CSF or plasma from
clinically predicted FTLD-tau and FTLD-TDP may ultimately
provide better biomarker possibilities and will require follow-
up in larger, longitudinal cohorts to test their sensitivity and
specificity. As such development occurs, it should do so with the
heterogeneity of FTLD in mind and potentially involve other neu-
rodegenerative diseases. Although one type of neuropathology
may be dominant and one brain region afflicted more than others,
cases of autopsy-confirmed FTLD may be further complicated by
concomitant Aβ, vascular or alpha synuclein pathology (National
Institute on Aging, 1997; McKeith et al., 2005; Toledo et al.,
2013). This is already apparent in some biomarker studies in
which perhaps as many as 30% of clinical FTLD patients are
also AD biomarker positive (Schoonenboom et al., 2012) and in
diagnostic imaging assays used for dementia with Lewy bodies
(DLB) where there may be significant overlap with FTD (Morgan
et al., 2012). In addition to AD and DLB, TDP-43 or phospho-
TDP-43 pathology can be found co-occurring with tau pathology
in cases of CBD, PSP, PiD and argyrophilic grain disease (Higashi
et al., 2007; Uryu et al., 2008; Arai et al., 2009; Fujishiro et al.,
2009; Rohn and Kokoulina, 2009; Yokota et al., 2010).
As a whole, these findings suggest that (1) clinical symptoms
are not wholly reliable as an indicator of an underlying pathol-
ogy or disease to be targeted for treatment; (2) an underlying
disease pathology at autopsy is not a guaranteed predictor of
a clinical phenotype; and (3) mixed pathologies and therefore
diseases are often coexistent. Additionally, moving earlier in dis-
ease course towards “cognitively normal”—as will be the desired
course for earlier administration of therapies—will increasingly
blur the diagnostic line between “normal” and disease, creat-
ing greater chance of false positives or negatives. This “messy
reality” of neurodegenerative disease means that a search for a
single, definitive disease diagnosis in individuals will probably
never achieve the same level of certitude as for diseases such
as viral or bacterial agents. That being said, with the advancing
sophistication of technology and data collection in medicine and
the decreasing cost of genome sequencing, it is not unrealistic
to envisage a combination of all or some of blood, CSF, and
genetic “panels” that contain large numbers of analytes or alleles
known to associate with different neurodegenerative pathology.
Initial probable diagnoses could be refined by subsequent imaging
studies. Such a multifaceted approach to disease diagnosis would
certainly have far greater power than those relying on singular
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FIGURE 3 | Potential FTLD diagnostic and therapeutic timeline. Clinical
trials in Alzheimer’s disease (AD) suggest that therapeutics will be
maximally effective when administered in early disease course. (1) Under
this scenario, simple and economically viable blood or cerebrospinal fluid
based screens at regular age intervals establish an individual’s biomarker
status at cognitively healthy baseline and also with respect to general
population. Screens include markers of all known disease pathologies
including Aβ, α-syn, TDP-43 and tau. Inexpensive genomic sequencing may
help to identify at risk individuals who require more regular evaluation.
(2) As pathology (or multiple pathologies) progress, regular screening
identifies deviations from the baseline that could potentially indicate early
stage disease, triggering more frequent evaluations. (3) Continued
biomarker positivity or progression justifies the use of more expensive
imaging methods to determine regional atrophy or using pathology binding
agents (such as florbetapir or as yet incompletely characterized tau binding
agents). Such data, when combined with CSF, blood and potentially genetic
alleles that associate with pathologies or sub types of pathology, may
provide potentially more predictive power than a reliance on a single
method. (4) Administration of single or multiple therapeutics depending on
results, continued follow up evaluations to test response to treatment. As
some individuals may be unresponsive to treatments, and future
therapeutics may not entirely halt disease progression, social support
structures including education and counselling for individuals and families
should be integrated into care.
readouts, and may be the only way to discriminate early stage
disease from “normal aging” as small deviations from the norm
across multiple analytes synergize to create disease pattern read-
out (Figure 3). However, such an approach would still only return
probabilistic diagnoses and has many considerations. Identifying
individuals at risk who should undergo diagnostic examination is
not a trivial issue. Determining who is screened, when, and how
often, both in trials and using any eventual treatment identified
is a priority. This may be based on a mixture of risk factors,
including age, family history, common place biochemical screens,
genetic risk alleles, or environmental risk factors that are cur-
rently unstudied (Onyike and Diehl-Schmid, 2013). Alternatively,
suspending testing until clinical symptoms manifest may be too
late in disease progression. Currently, we do not know at what
stage intervention might be required and determining this by
trial and error will be time consuming and financially costly.
Furthermore, decades of unsuccessful clinical trials would also
exact a human toll, and for this reason, it is important that
social support resources be available to patients and families.
Undoubtedly, clinical trials will necessitate great foresight and
planning and such considerations will need to be debated prior
to implementation of therapeutics.
CONCLUSION
As outlined above, the ability to use biomarkers to identify
specific subtypes of underlying FTLD-TDP or FTLD-tau in
early stage disease (whether prodromal or asymptomatic phases)
is a challenging issue, but one of paramount importance if
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the experiences of AD clinical trials in symptomatic patients
also extrapolate to FTLD. Further complication arises regard-
ing the complexity of disease. At the outset of studies focus-
ing on tau, the prevailing theory was that removal of NFTs
would provide a therapeutic breakthrough. Years on, that notion
seems oversimplified and tauopathies are recognized as extremely
complex, with an abundance of biochemical and structural tau
alterations that may all, in some form or other, contribute
to neuronal demise through mechanisms that are as yet not
fully understood. Furthermore, such processes may not be a
single linear mechanism, both in the formation of detrimental
tau species and in their effect. It is inevitable that increased
study will reveal an even greater complexity and this is highly
probable for FTLD-TDP also. Although this means that we
are increasingly knowledgeable about neurodegenerative mech-
anisms, it also suggests that these are multifactorial, multi-
mechanistic diseases that current technology may find difficult
to address. In this respect, it is possible that in addition to
the “knowledge gaps” highlighted above, we may face some-
what of a “technology gap”. Compared to the myriad biochem-
ical changes in tau, TDP-43 and other cellular processes, all of
which occur in different cell types at various stages between
healthy and degenerating, delivery of a single pharmaceutical
compound aimed at a sole process or pathway to the whole
brain may be oversimplified. The invention of novel technologies
or use of multiple, simultaneous therapeutic strategies may be
required. In the interim, care must be taken in the selection
of therapeutics going forward as financing of trials for ther-
apeutic interventions will not continue in aeternum if strate-
gies based on unproven mechanisms fail repeatedly in clinical
trials.
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